Introduction
Nuclear receptors (NRs) represent a family of ligand-dependent transcription factors, united by common functional mechanism and domain architecture. At least 13% of marketed drugs target NRs. 1 The two key domains, the ligandbinding domain (LBD) and the DNA-binding domain (DBD), are conserved in most NRs and are surrounded by the more variable regions (N-terminal, hinge region and C-terminal domains). NR LBDs recognize, sometimes with picomolar affinity, small membrane-diffusible endogenous hormones, metabolites or xenobiotics. A ligand binding event induces reorganization of complex intra-and intermolecular interactions, which ultimately leads to the formation of a complex between the NR DBD and the hormone response element of the target DNA and consequently to either initiation or repression of the target gene transcription. Nuclear receptors are found in metazoans While most human NRs (with the notable exception of pregnane X receptor) are fairly specific, many of the marketed NR modulators exhibit varying degrees of polypharmacology. Furthermore, it has been demonstrated that some environmental substances and their metabolites bind to NRs, resulting in the disruption of endocrine signaling pathways and developmental defects. 2, 3 Understanding the structural and molecular basis of the specific binding of small molecules to the LBDs of NRs represents an important challenge for both structural computational chemistry and green chemistry. Translation of this understanding into predictive chemistry-unbiased and training-independent models may lead to a new generation of safer therapeutics and early alerts concerning dangerous environmental chemicals.
Therapeutic agents and environmental chemicals may affect NR-mediated gene expression in several ways, e.g., by mimicking endogenous hormones (full and partial agonists), sterically blocking activation by endogenous hormones (antagonists) or inhibiting the basal ligand-independent transcription activation (inverse agonists). While any of these activities requires binding to the LBD, the specific mode of action of a chemical modulator (agonism or antagonism) may depend on many factors. Some modulators block binding and activation of the receptor by an endogenous agonist when the latter is sequence similarity of their LBDs. The receptors are classified into seven subfamilies (NR0-NR6), which are further divided into groups. The nodes on the tree are marked by the abbreviated conventional name of the receptor (e.g., PPARc for peroxisome proliferator-activated receptor c) and also their group and member ID within the subfamily (e.g., NR1C3). The number of LBD structures available in the PDB for each receptor at the time of publication is given in Table 5 .1 and is represented by the volume of the spheres. present in sufficient quantities, therefore acting as competitive antagonists. However, in the absence of the endogenous agonist, the same compound can weakly activate the receptor, acting as a partial agonist. The effects of the drug may also depend on the fine balance of receptor isoforms, co-activators and co-repressors, number and location of hormone response elements, and the presence and activation state of other transcription factors in a specific tissue or a cell type. 4 These factors explain the phenomenon of tissue selectivity and enable the development of tissue-selective NR modulators. Structurally, such compounds are believed to affect the equilibrium between active and inactive conformations of their target receptors, which in turn is interpreted by the organism in a tissue-specific manner. Tissue-selective modulators are known for several receptors, including estrogen receptor (ER), 5 androgen receptor (AR), 6 glucocorticoid receptor (GR) 4, 7 and progesterone receptor (PR). 8 NRs evolved to interact with different classes of molecules (e.g., steroid hormones, fatty acids or phospholipids); therefore, they manifest substantial sequence and structural variability in the LBD; however, within the families or subfamilies of related receptors, ligand-receptor cross-reactivity frequently occurs. Some of this cross-reactivity results in physiological or adverse effects of therapeutics. The concept of NR subtype cross-reactivity is illustrated by the androgenic effects of early contraceptives. 9, 10 Even after the extensive subtypeselective optimization that these drugs underwent in recent years, the beneficial side effects of combined oral contraceptive pills, and also unpleasant withdrawal symptoms, are partially due to off-target interaction of progestogens with the mineralocorticoid receptor.
The growing wealth of structural information about the NR LBDs provides a unique opportunity for the development of physical structural models that explain the observed activity and cross-reactivity and predict the endocrine effects of drugs and xenobiotics. For the last 15 years, individual crystal structures have been used successfully to discover new drug leads or molecular probes by docking-based virtual ligand screening. Some examples include computational identification of retinoic acid receptor agonists 11 and antagonists, 12 thyroid hormone receptor antagonists 13 and pregnane X receptor agonists, 14 in addition to the repurposing of antipsychotics as androgen receptor antagonists. 15 However, methods are still needed to improve the specificity and selectivity of the computational predictions, to profile compounds against the extended nuclear receptor panel in silico and to predict functional activity.
This chapter summarizes and analyzes the structures of the LBDs of the human NRs, and also the two-dimensional (2D) and three-dimensional (3D) chemical information about their chemical modulators. We demonstrate that multiple co-crystal structures of the same LBDs may improve the ability of the ligand docking and scoring methods 16 to recognize chemically diverse modulators and may result in more accurate chemistry-unbiased predictive models of activity. We also show that the 3D coordinates of co-crystallized modulators alone can be converted into 3D pharmacophore property models that, in turn, can be used to recognize potential modulators by docking/ scoring. These approaches can also be treated as complementary. The aggregated data, models and methods may lead to the discovery of drugs with improved NR profiles or the early discovery of endocrine risks of environmental chemicals. 18 21 of the 48 receptors were described as orphan, by now at least one sub-micromolar endogenous or exogenous activator has been identified for 10 of these orphan receptors, which is reflected in either crystallographic or medicinal chemistry databases (Table 5 .1). Several receptors that have only been crystallized in the apo form manifested the absence of the binding pocket, which may be, but not always is, the inherent feature of the receptor relating to its inability to bind any ligands. Nerve growth factor IB (NGF IB, also known as NUR/77 or NR4A1) is an example of a receptor whose X-ray crystal structure does not have any internal cavity; however, it is now known that cytosporone B is its naturally occurring agonist 19 and additional synthetic NGF IB agonists have been also identified. 20 The apparent inconsistency is probably due to the natural flexibility of the NGF IB binding pocket that tends to collapse in a crystallographic environment in the absence of the ligands. NGF IB provides a clear example of the conformational plasticity of the NR LBDs and the widely varying utility of crystallographic structures for augmenting our understanding of NR ligand binding and specificity.
Chemicals
Depending on the degree of the conformational plasticity of the LBD, and also on the precise arrangement of the pharmacophore features of the residues in the pockets, some nuclear receptors may be more picky towards their ligands than others. The distribution of ligand MQN properties (shape, size and atom composition 21 ) varies from extremely wide in pregnane X receptor (PXR) to very narrow in vitamin D receptor (VDR) ( Table 5. 2). This kind of ligand property distribution analysis not only reflects the biological properties of the receptors (e.g., it characterizes PXR as a promiscuously activated transcription factor), but, as we will show below, also gives preliminary insights into the level of difficulty of ligand activity prediction for each individual receptor. Hepatocyte nuclear factor 4 c 
Agonists, Antagonists, SNuRMs
Most endogenous chemicals targeting NRs function as agonists and lead, depending on the receptor type, to either activation or repression of target gene transcription. In contrast, therapeutic agents belong to several classes: whereas some mimic the action of the endogenous agonists (e.g., rosiglitazone and bexarotene), others bind to the target domain, preventing downstream signaling or transcriptional activity changes. Moreover, they prevent stimulation of the receptor by the endogenous agonists by competing for the same binding site (e.g., mifepristone, RU486). Drugs with a mixed agonistantagonist profile often modulate the signaling by their target receptor in a tissue-selective manner and are called selective nuclear receptor modulators (SNuRMs). Following the serendipitous discovery of tamoxifen, as a tissueselective estrogen receptor modulator that acts as agonist in the bone and as an antagonist in breast, 5, 22 with both actions leading to beneficial therapeutic effects, there has been growing interest in the development of SNuRMs for other receptors.
Although the early therapeutic agents targeting NRs were close chemical analogs of the endogenous hormones, chemically divergent modulators are now known for best studied receptors, e.g., non-steroidal agonists and antagonists of the steroid receptors. In many cases, drugs of novel chemical classes are characterized by improved pharmacokinetic properties compared with the analogs of endogenous agonists.
The chemical features that distinguish agonists from antagonists are not always obvious, in agreement with the complex structural basis for LBD activation (see Section 5.3.2). Estrogen receptor antagonists are distinguished from agonists by a bulky ionizable 'side chain' that, in the bound state, extends towards the opening of the ER binding pocket, sterically interfering with the active conformation of helix 12. However, a large number of NR antagonists do not have this bulky side chain (e.g., flutamide). Moreover, even with closely related receptors, a single chemical may act as an agonist for one and an antagonist for the other. For example, progesterone is an agonist for the progesterone receptor but an antagonist for the closely homologous mineralocorticoid receptor, while the synthetic estrogen THC acts as an agonist and an antagonist for the estrogen receptor subtypes a and b, respectively. 23 
Analysis of Cross-reactivity
A comparison of chemical activity sets for individual NRs also provides insight into the degree of their cross-reactivity, i.e., the ability of different NRs to be activated by the same ligands. Figure 5 .2a illustrates the principles of calculation of cross-reactivity potential of pairs of NRs based on similarity of their ChEMBL ligand activity sets in the spirit of ref. 24 . Given two sets of chemical activities measured against receptors A and B, a pairwise measure of compound similarity (in the presented plot, Tanimoto distance on chemical fingerprints) is calculated for all compound pairs within the activity set A, all pairs within the set B and all pairs between the two sets. Three cumulative distribution curves are constructed, each plotting the fraction of pairs in the set (or between the sets) that fall under a specified distance cutoff against that cutoff. Next, the distribution of pairwise distances between the two sets is compared with each of the intra-set distributions. The two sets appear well separated in the chemical space if at low chemical distance cutoffs, there are significantly fewer inter-set pairs below the cutoff than there are intra-set pairs. In this scheme, the definition of the 'low chemical distance cutoffs' is rather arbitrary; we chose to introduce a continuous weight function W(D) 5 exp ( The proposed chemical set similarity measure takes into account not only the number of similar compounds between the sets, but also the degree of 'chemical spread' within each of the sets. Comparing a 'tighter' set with a set with wider 'spread' results in a larger value than comparing the same two sets in reverse order. This is because a related compound has a higher probability of accidentally hitting a target that is inherently more promiscuous. The concept is illustrated by a pairwise comparison of the chemical activity sets for the three peroxisome proliferator-activated receptors (PPARs), a, d and c. This comparison demonstrates that there is a high probability of hitting the d isoform with a compound from the a set [Sim(d,a) 5 0.32] and a lower but still significant probability of hitting the a isoform with a compound from the d set [Sim(a,d) 5 0.1]. This correlates with the well-documented difficulties in the design of a-and d-selective PPAR agonists, and also with smaller number of compounds that are selective for PPARa versus PPARd.
At the time of writing this chapter, low nanomolar modulators could be found in ChEMBL for 27 human nuclear receptors. The 27 6 27 matrix of ChEMBL set similarities ( Figure 5 .2b) calculated as described above reveals non-trivial relations in addition to the expected cross-reactivity between the closely related receptor subtypes. For example, it shows that the ligands for the NR3C family of receptors (GR, MR, PR and AR) have a substantial probability of hitting the pregnane X receptor.
We show in this chapter that computational models based on 3D crystallographic structures of the NR LBDs are highly instrumental not only for the prediction of ligand activities, but also for ligand profiling and for identification of subtype-selective modulators.
Nuclear Receptor Ligand-binding Domains

Structural Coverage
As of December 2011, X-ray structures had been solved for 37 of the 48 human NRs, often in complexes with multiple high-affinity modulators. With only a few exceptions, each receptor is represented by multiple (co-)crystal structures. Even for the single-entry receptors, one can typically find multiple instances of the protein in an asymmetric unit (e.g., four variations in the PDB entry 2GL8 for RXRc). Each of ERa, VDR, AR, RXRa and PPARc are represented by over 30 PDB entries with many more individual variations of the pocket. This increases our understanding of possible induced fit effects, and also, in some cases, the structural mechanisms underlying the phenomena of agonism, antagonism or allosteric modulation. The wealth of information about liganddependent structural variability of the protein binding pockets and the resulting functional response diversity of the proteins is well represented in the Pocketome database, 25 a large part of which is composed of the NR LBDs. All LBDs of the NRs share a similar topology, shown in Figures 5.3 and 5.4. The LBDs crystallized so far reveal a highly structurally conserved a-helical fold with a deep well-protected 'abdominal' cavity; the 'entry door' to the cavity is formed by helices H11-H12 and the 'back' wall is an anti-parallel bsheet of variable size.
Structural Basis of Agonism and Antagonism
NR agonists usually act by stabilizing a specific conformation of the LBD. This conformation is characterized by a snug fit between a hydrophobic residue at the base of H12 and four other residues in helices H3, H5 and H11. The obtained 'pyramid' of interactions ( Figure 5 .5) effectively leads to the formation of the co-activator peptide-binding interface on the surface of helices H3, H4 and H12 and consequent co-activator recruitment. In contrast, small molecules that prevent the formation of the pyramid act as either pure antagonists or tissue-selective modulators, depending on the degree of pyramid destabilization. The latter class of molecules is the most interesting: they only partially destabilize the active 'pyramid' conformation so that it remains one of several equilibrium conformations of the LBD, and the downstream functional effects become entirely dependent on the relative concentrations of coactivators, co-repressors and other binding partners in the specific tissue.
Destabilization of the 'pyramid' by drugs may have a more or less pronounced effect on the overall conformation of the LBD. In the NR3A and NR3B family of receptors (estrogen and estrogen-related receptors), antago- Mutations of 'pyramid' residues may result in a receptor that is either constitutively active or accommodates wild-type receptor antagonists, while retaining the productive co-activator-binding conformation. These mutations have a selective advantage in hormone-dependent cancers: for example, the well-characterized T877A and W741L mutations in the AR that evolve in a prostate cancer patient as a result of treatment with anti-androgens (e.g., flutamide, bicalutamide) and confer agonist activity on these drugs, belong to the class of pyramid residue mutations.
In many cases, the effect of destabilization of the active conformation by antagonists or SNuRMs is so subtle that it can be completely or partially reversed by the crystallographic environment of the LBD in an X-ray structure. Consequently, in crystallography, antagonists and SNuRMs are sometimes observed bound to the active conformation of the target domain. 26 In the context of structure-based prediction of ligand activity, this means that apart from the ligand itself, an LBD X-ray structure may not necessarily carry the information about the functional class of its cognate modulator. Pocket structures crystallized with antagonists usually recognize agonists well in virtual ligand screening. The opposite may also be true, although it occurs less frequently.
Computational Prediction of Nuclear Receptor Modulators
While crystallography of the NR LBDs assists our understanding of the structural principles of ligand interactions with their target receptors, the ultimate goal of computational NR biology is the prediction of affinity, activity and selectivity profiles for novel compounds. For that, the crystal structures need to be converted into predictive models and carefully benchmarked in retrospective applications. The two complementary approaches to the problem address it from the side of the binding pocket and from the side of the co-crystallized ligand. In both cases, the prediction is based on the docking of flexible compounds, with consequent scoring of the lowest energy compound poses 27 and ranking of the compounds based on the scores obtained. Below we outline these approaches, the applicability domains of the resulting models and difficulties associated with model generation.
Improving the Docking and Scoring Accuracy to Ligandbinding Domains
Flexible ligand docking into NR models can be categorized into the following cases of progressively more uncertain and error-prone procedures:
(a) (the safest) docking to multiple, conformationally distinct models derived from multiple co-crystal structures of the same protein; (b) docking to a single model derived from one crystal structure and compound screening; (c) docking to homology models; (d) docking of an antagonist to a LBD model derived from co-crystal structure with agonist; (e) docking to allosteric sites.
Each category has distinct challenges and the expected success rate in terms of both ability to predict the correct binding pose and use the docking/scoring for predicting activity of new compounds deteriorates very quickly from almost perfect results for the majority of nuclear receptors in the (a) category to a risky gamble for (c), (d) and (e).
Docking to Pockets Obtained from Multiple Co-crystal Structures
From observing the multiple co-crystal structures of a single LBD, it becomes obvious that a certain conformational variability of the pocket is an inevitable attribute of the induced fit of ligand binding. In extreme cases (e.g., NGF IB), the crystal structure pocket can collapse entirely and prohibit any ligand binding, despite the fact that the receptor is known to bind and be activated by ligands (Section 5.2.1). In more subtle cases, it often appears that some pockets favorably dock and score multiple ligands that belong to different chemical classes, others only recognize a single chemical and down-score the other highaffinity binders, and the rest are not selective at all in scoring the known binders against random inactive molecules of matching size and physicochemical properties. In other words, the screening performance of individual X-ray structures of a single LBD may vary greatly due to major or minor variations in the pocket conformation.
In the situation when a sufficiently large amount of medicinal chemistry data is available for the given receptor, in the form of chemicals and their affinities and activities, the quality and utility of a pocket model can be evaluated by retrospective screening. In this procedure, the known actives are mixed in a single dataset with decoy molecules of matching size, molecular weight, atom counts, logP, etc. (the so-called property-matched decoys), followed by docking and scoring to the model. A model with good selectivity consistently ranks known actives better than decoys, resulting in ideal (or close to ideal) shape of the receiver operating characteristic (ROC) curve with the area under the curve (AUC) being close to 1. In contrast, a bad model ranks actives and decoys equally well, resulting in an approximately straight diagonal ROC curve (AUC 5 0.5) or sometimes even ranks actives worse than decoys (AUC close to zero).
Because the conformational variants of a single LBD may recognize distinct classes of chemicals, it is important to include a representative ensemble of those essential conformations as multiple independent models (so-called ensemble docking, e.g., ref. 28) , as concurrently present 'four-dimensional' grid potentials. 29 We recently tested 17 NRs for single versus multiple receptor performance and the multiple conformation performance was consistently better than an average single conformation. 16 However, it is not as simple as 'the more the better'. Three important non-trivial caveats need to be stated. N First, as described above, for receptors with multiple experimental crystal structures, the screening performance measured as ability to separate actives and decoys by docking and scoring may be highly variable between individual models. 16 The choice of a structure representing the pocket can dramatically change the screening outcome.
N Second, including all models in the ensemble and selecting the lowest score usually decrease the success rate for screening and recognition ( Figure 5.6 ), because each additional crystal structure and conformation not only gives a possible induced conformation, but also increases the chance for a decoy to have lower score, therefore increasing the 'noise'. Since the number of decoys (or non-actives) far exceeds the number of actives, this factor becomes dominant in a screen.
N Third, partially because of the above reason, it is possible that a single conformation gives a better ROC AUC value than multiple structures with a given set of actives and decoys. For example, a single refined model for PPARc produces impressive AUCs of 0.94 and 0.92 for the DUD 30 and Wombat 31 sets, respectively. 32 Practically, we employ the following recipe:
N Choose a set of actives (A) and decoys (D) for a given pocket from an activity database, e.g., ChEMBL.
33
N Perform initial refinement (hydrogen placement, Asn, Gln, His rotations) of each model with a cognate ligand and remove ligands to create a pocket.
34
N Evaluate the ICM docking and scoring performance of each available cocrystal structure, by retrospective screening of known actives against relevant decoys and measuring the resulting area under ROC curve (AUC).
N Choose one or several models that collectively provide the best separation between actives and decoys. The aggregated score is the lowest score for a given compound.
As can be seen from the distributions in Figure 5 .6, this approach provides excellent models for over 60% of the nuclear receptors. These models assign docking scores better than the 0.1% of the decoys for anywhere from 20 to 99% of the ChEMBL-annotated actives even with over 20-fold more decoys with matching properties.
However, for certain receptors, such as the glucocorticoid, mineralocorticoid, pregnane X and liver X receptors, these selected and lightly refined multiconformational models are not sufficient. Some of the difficulties are clearly related to the larger cavities, naturally designed to accommodate a wider variety of chemicals. In other cases, potential reasons for poor screening performance could include the insufficient refinement of the cognate structures or insufficient conformational repertoire of pockets. Finally, avenues for screening performance improvement also include separation of the distinct functional states within the ensembles, accounting for essential water molecules and their displacement and improving the accuracy of 2D to 3D conversion of complex steroid cores.
Each ROC curve shows how actives and decoys are separated by the predicted docking scores. However, the range and the distribution of those scores depend on a protein and, to a lesser extent, on a model representing the protein. To predict an activity of a new compound, one needs to know if the score of the compound fits within the decoy score distribution or if it is significantly better than decoy scores, which justifies any assumptions made about its activity. In order to provide a compact and robust representation of the decoys score distribution, one may numerically fit it into an analytical function and store the resulting fit parameters. The parameters can then be used to calculate both the normalized score for a new compound or a probability of its inactivity.
In summary, the refined multi-conformational models represent an ultimate recognition device for new chemistry once one or several co-crystal structures have been determined. They can be used for virtual ligand screening, activity Figure 5 .6 Virtual screening performance of the NR models based on optimal pocket conformation ensembles (black curves), all-inclusive ensembles (dark-grey curves), best single conformation (light-grey curves), and ligand atomic property fields (APF, colored curves). The actives were selected from ChEMBL activity datasets with an adaptive activity cutoff: 10 nM for receptors with more than 20 low-nanomolar modulators and decreasing to at most 100 nM for receptors with fewer high-affinity modulators. The decoys were selected from virtual databases of commercially available compounds based on the similarity of chemical properties (molecular weight, logP, atom counts, charge, etc.). The number of actives and decoys is shown on each plot. For APF models, the number of seed molecules used to build each model is also shown. ROC curves provide retrospective evaluation of the screening performance of each model in question. prediction and individual compound profiling, once the parameters of the noise distribution have been derived from a large number of decoy scores.
Docking and Screening Against a Single Crystal Structure
Docking molecules into a single crystal structure was traditionally viewed as the mainstream docking and screening tool. However, there are three important caveats to be taken into consideration.
First, a model deposited in the PDB may need additional refinement or modeling within the limits of the experimental electron density to address five issues: (i) placement and optimization of rotatable hydrogens; (ii) optimization of orientations of Asn, Gln and His and tautomeric/protonation states of His (six states of each His side chain are compatible with the electron density); (iii) optimization of the parts of the model in the regions of unclear electron density; (iv) overall small positional adjustments to ensure more realistic packing with the co-crystallized ligand; and (v) selection of water molecules to be retained in the pocket. All these changes do not change the fit of the model to the electron density but produce a much more realistic and, in the end, efficient model for screening.
Second, although the optimized model may now be used for virtual ligand screening of new chemicals that may potentially bind to this pocket, it is relatively useless in predicting the activity of a new chemical scaffold, since a single receptor conformation is expected to recognize only a subset of the actives and have a sizeable fraction of false negatives.
Third, the models may be further manipulated to accommodate larger antagonists by moving parts of the H11-H12 loop and helix 12.
The internal coordinate (ICM) docking to a single conformation has been used successfully for screening for new chemical leads over the last 12 years. In 2000, two new retinoic acid receptor antagonists were discovered by virtual ligand screening of a model in which helix 12 was moved away to resemble the antagonistbound conformations of estrogen receptor. 12 In 2001, 150 000 molecules were screened against a single RAR model without modification, 30 molecules were tested and two new potent agonists (K i , 50 nM) were discovered. 11 In 2003, a homology model was built for the thyroid hormone receptor LBD and it was used to screen a 250 000 compound library. Out of 64 compounds tested, 14 were found with antagonistic activity ranging from 1.5 to 30 mM.
13
As we depart from a refined model into predicted states and homologous proteins, the success rate is no longer guaranteed. It may also require some 'ligand guidance' to make sure that the model at least binds several reference molecules favorably. In the first use of this technique, 35 two antagonist-bound models of the androgen receptor were generated using the ligand-guided procedure and the resulting models were used to identify androgenic activities of some antipsychotic drugs. This is also an example of docking-based drug repurposing.
In conclusion, although virtually screening a compound database against a single crystal structure can be a possible screening tool with over 5-10% early success rate, this screen is bound to miss many active molecules. Furthermore, the models may need refinement and sometimes further manipulation to accommodate alternative functional states.
Ligand-derived Atom Property Fields from Co-crystal
Structures as Activity Predictors (Table 5 .1), more than one ligand has been cocrystallized with the LBD. These ligands can be naturally overlaid in space by superimposing the surrounding binding pockets. Following such superposition, the collective location of atoms of specific types in space presents valuable information that can be used in docking-based prediction and characterization of ligand activities. Specifically, compounds will be flexibly docked to and scored by the chemical property fields derived from the experimental ligand positions ( Figure 5 .7a-c).
The atomic property field (APF) method was developed fairly recently. 17 It represents the pharmacophore features of the superimposed high-affinity ligands (referred to as APF seeds) by seven continuous fields calculated in a three-dimensional grid. These seven fields represent the following properties: hydrogen bond donor and acceptor potential, sp 2 vs sp 3 hybridization, lypophilicity, size, charge and electronegativity. Each atom can contribute to multiple properties and the property peaks are smoothed in 3D space according to a Gaussian distribution with a given radius ( Figure 5 .7a). The radius of 1.4 Å was used in the docking simulations presented here. The multiple APF seeds may contribute differently to the APF fields depending on their experimentally measured binding affinities, pharmacokinetic properties, etc.
The cumulative 3D property fields can be used for docking and scoring of new compounds in exactly the same manner as receptor grid potential fields are used in docking to the receptor pocket. 36 However, the target function to be optimized now has to include the intramolecular energy of the compound in combination with the APF-fit energy calculated from the cumulative APF fields. Thorough sampling of each compound in the 3D space results in an energetically favorable conformation that best fits the atomic property fields and its APF fit score can be used as a predictor of the activity of the compound against the receptor in question.
To illustrate the utility of this approach, we constructed APF fields for all 25 NRs with available 3D seeds in the PDB. The multiple copies of identical chemicals were excluded from the process to avoid overrepresentation of selected chemical scaffolds. For simplicity, each unique crystallographic ligand was represented with an equal weight. The models obtained were validated in retrospective screening for known high-affinity modulators of the target This screen, however, also highlighted the drawbacks of the APF approach and the limits of its applicability. In particular, it showed that when there are only a few seed ligands and the seed ligands are chemically distinct from the majority of active compounds, the APF model may not be capable of providing any recognition (exemplified by the case of ERRa, Figure 5 .7d). Also, wide chemical variations between the ligands and a large volume of the binding pocket resulted in a poorly defined APF field, which was not selective towards known actives (e.g., PXR, Figure 5 .7e).
As is, the APF docking approach does not penalize the bulky compound fragments that do not fit into the APF density, provided that the core aligns well. Consequently, the superstructures of the active compounds score at least as well as the active compounds themselves, although in reality they may be too bulky even to fit sterically in the pocket. To address this issue, one needs to introduce an additional grid potential in APF docking that represents the prohibited regions in space, the so-called excluded volume. Adding this component is expected to improve the APF screening performance in realistic settings, where the properties of the inactive compounds do not necessarily match with those of the actives.
Prediction of Ligand Selectivity and Polypharmacology
The importance of finding subtype-selective modulators for NRs cannot be overestimated. The effects mediated by binding of drugs to the close (or not so close) homologs of their target receptors adds a new level of complexity to the profiles of action in the human body (e.g., ref. 37). The 3D receptor-based and ligand-based models described above can be used not only to predict highaffinity modulators for a given receptor, but also to derive relative propensities of a single compound to different NRs. The additional challenge is created by the fact that here the active compounds have to be distinguished not from property-matched decoys, but from actives for another, sometimes closely related, receptor.
The binding scores calculated for each ligand and each receptor model as described above may provide some information about the relative affinity. However, although the scores can capture the relative ranking of different compounds for the same receptor well, they are not always accurate enough to represent the absolute binding free energy. An attempt was made to use the raw scores for 19 models of different NRs for selectivity profiling. 38 Although a certain level of success was achieved, the raw score against single models had only limited discrimination power. The reasons for non-ideal discrimination can be narrowed down to the following contributions: (i) the proteindependent part of the binding energy that is not included in the docking score, e.g., the protein-dependent entropy loss upon ligand binding; (ii) a pocket conformation -the accuracy of different models may be different and systematic geometric errors or features may shift the binding score consistently up or down; (iii) other errors or simplifications of the pocket model including partial atomic charges, individual strength of hydrogen bonds, etc.
The systematic protein-dependent score shift can be taken into account by introduction of score offsets. The distribution of the scores from a large decoy set is calculated and shifted so that the edge of the noise distribution corresponds to the zero binding score. The offset was defined as the 5th percentile of the best scores from the decoy distribution, where the decoys were defined as the whole database of nuclear receptor ligands. 16 These naïve offsets improved ligand-receptor recognition by the shifted score. The offset can be further optimized by a more detailed fitting algorithm, but for the NRs considered, 16 it made relatively small changes in the offset. The shifted scores reduced the false positives coming generally from the better scoring pockets. The same method can further be applied to fine-tune individual scores coming from different conformations of the same protein.
The ligand-based 3D activity models described above can also be used for compound profiling. To illustrate their ability to predict selective compounds, we chose two sets of closely related NR subtypes: peroxisome proliferatoractivated receptors (PPARs) a, d and c and NR3C family receptors, androgen, progesterone, glucocorticoid and mineralocorticoid receptors. Within both classes, substantial cross-reactivity is observed, as shown in Figure 5 .2b. In each case, the selectivity of compounds targeting one subtype was distinguished from subtype-selective modulators of others. Figure 5 .8 shows that a substantial initial enrichment is observed when the PPARd model is used to screen for PPARd-selective compounds, but not when PPARa or PPARc models are used instead. On the contrary, PPARc-selective ligands are clearly more accurately recognized by the PPARc model than by PPARa or d models. As with any other method, APF has its weaknesses. For example, all related subtype models appear to have approximately the same level of selectivity when an attempt is made to identify PR-selective ligands or PPARa-selective ligands.
The score offset approach is not applicable to the APF docking because APF scores are calculated on a different scale. To yield an absolute APF-based compound activity and selectivity profile predictor, the scores need to be further normalized. One way of doing it is to analyze the score distribution for decoy/inactive compounds and assign each score with a probability of observing this score for an inactive compound. As described above (Section 5.4.1.1), fitting the decoy score distribution into an analytical function (Gaussian or extreme value distribution function) with subsequent evaluation of parameters of this function provides a compact and accurate way of accounting for protein-specific binding score offsets. For each new compound, a linear transformation of a raw docking score followed by a p-value evaluation provides an activity call for a ligand-receptor pair.
